- Home
- DCOM vs SYRE Comparison
DCOM vs SYRE Comparison
Compare DCOM & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DCOM
- SYRE
- Stock Information
- Founded
- DCOM 1864
- SYRE 2013
- Country
- DCOM United States
- SYRE United States
- Employees
- DCOM N/A
- SYRE N/A
- Industry
- DCOM Major Banks
- SYRE Biotechnology: Pharmaceutical Preparations
- Sector
- DCOM Finance
- SYRE Health Care
- Exchange
- DCOM Nasdaq
- SYRE Nasdaq
- Market Cap
- DCOM 1.2B
- SYRE 1.2B
- IPO Year
- DCOM 1996
- SYRE 2016
- Fundamental
- Price
- DCOM $27.65
- SYRE $17.94
- Analyst Decision
- DCOM Buy
- SYRE Strong Buy
- Analyst Count
- DCOM 4
- SYRE 8
- Target Price
- DCOM $35.50
- SYRE $51.50
- AVG Volume (30 Days)
- DCOM 284.9K
- SYRE 664.6K
- Earning Date
- DCOM 04-22-2025
- SYRE 05-08-2025
- Dividend Yield
- DCOM 3.64%
- SYRE N/A
- EPS Growth
- DCOM N/A
- SYRE N/A
- EPS
- DCOM 0.55
- SYRE N/A
- Revenue
- DCOM $277,986,000.00
- SYRE N/A
- Revenue This Year
- DCOM $50.86
- SYRE N/A
- Revenue Next Year
- DCOM $15.62
- SYRE N/A
- P/E Ratio
- DCOM $51.33
- SYRE N/A
- Revenue Growth
- DCOM N/A
- SYRE N/A
- 52 Week Low
- DCOM $17.49
- SYRE $16.71
- 52 Week High
- DCOM $37.60
- SYRE $40.84
- Technical
- Relative Strength Index (RSI)
- DCOM 37.50
- SYRE 43.06
- Support Level
- DCOM $27.82
- SYRE $16.71
- Resistance Level
- DCOM $29.32
- SYRE $19.50
- Average True Range (ATR)
- DCOM 0.86
- SYRE 1.28
- MACD
- DCOM 0.10
- SYRE 0.07
- Stochastic Oscillator
- DCOM 36.50
- SYRE 42.86
About DCOM Dime Community Bancshares Inc.
Dime Community Bancshares Inc operates as a holding company. It gathers deposits from customers within its market area and via the internet and invests them in multifamily residential, commercial real estate, commercial and industrial (C&I) loans, and one-to-four family residential real estate loans, as well as mortgage-backed securities, obligations of the U.S. government and government- sponsored enterprises (GSEs), and corporate debt and equity securities. The company has one reportable segment which is Community Banking.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.